BioMarin Pharmaceutical Inc.: Canaccord Genuity raises target price to $117 from $114
BMRN•Canaccord Genuity raised its target price for BioMarin Pharmaceutical Inc. to $117 from $114.
Related News

Alico presents strategy to target 25% of land holdings for development
ALCO•

AI Era acquires AI script-to-video technology for $3 million
AERA•

HomeServices of America names Maria Latushkin chief technology officer
BRK.B•

Meta adds Loblaw as first Canadian retail partner for Muse
META•

BRC Group Holdings chairman and co-CEO Bryant R. Riley reports $116,767.20 share acquisition
RILY•